10 stories about Pfizer
מארק האפלה מנהל השקעות ראשי בחטיבת ניהול ההון של UBS

Mega-cap tech firms could lag the market next year, but tech in general won't underperform, says UBS chief investment officer

06.12.20|Sophie Shulman
Mark Haefele, Chief Investment Officer at UBS Global Wealth Management, says that stock markets will rise and fall depending on how quickly Covid-19 vaccines are approved and distributed
מנהל המכון הביולוגי נס ציונה פרופ' שמואל שפירא

“Excessive regulation” to blame for delay in Israeli Covid-19 vaccine says professor in charge

Director of the Israel Institute for Biological Research says vaccines will be distributed in the summer of 2021
כיתוב אוניברסיטת ת"א פרופ גרשוני

New innovative vaccines by Moderna and Pfizer are safe, says top Israeli virologist

24.11.20|Yafit Ovadia
“There isn’t any need for alarm,” says virologist about new coronavirus vaccines
חיסון קורונה פייזר אילוסטרציה

After a coronavirus vaccine is approved, what happens next?

22.11.20|Sophie Shulman
On Dec. 10, the FDA is expected to announce whether it will approve Pfizer’s new vaccine, but 2 trillion people will not receive it until the end of 2021
מימין דרק זנוטו יבגני דיברוב ועידת ניו יורק

Markets may recover from pandemic soon, says CapitalG investor

Vaccine announcements, possible removal of U.S. travel ban and other factors will contribute to economic recovery, senior investors say in Calcalist and CTech’s Mind the Tech virtual conference
ד"ר טל זקס מנהל רפואי מודרנה

Moderna’s chief scientist says company initiated vaccine deal with Israel

16.11.20|Sophie Shulman
Israeli scientist Tal Zaks says Israel will be among the first to receive doses from the company’s European plant
מטה חברת תרופות פייזר ניו יורק

Pfizer and BioNTech claim 90% effective rate for their Covid-19 vaccine

The news comes at the same time that Israel is currently undergoing human trials of its own vaccine for deployment in 2021
חיסון תרופה קורונה אילוסטרציה

As the Covid-19 vaccine arms race intensifies, big money is at risk

10.08.20|Sophie Shulman
Governments want to be among the first to get their hands on the coveted solution, but they are also risking money that could be used to strengthen their healthcare system
הדמיה חיסון תרופה קורונה covid 19

Place your bets: Which company will reach a Covid-19 vaccine first?

02.08.20|Sophie Shulman
Moderna may be creating all the buzz, but it is the youngest and least experienced of the contestants, playing an all or nothing game
בריאות דיגיטלית מדעי החיים רפואה טיפול 1

Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason

10.01.19|Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars